Comunicati Stampa
Servizi

PharmaVentures acts as exclusive M&A advisor to the PE firm capiton AG on the successful sale of MiP Pharma's Sterile Production Facility to FAMAR Group

The pharmaceutical services sector that includes CROs, CDMOs and other specialist consultancies continues to evolve and transactions such as this are a key driver for the growth of Pharmaceutical Services companies. The pharmaceutical services sector that includes CROs, CDMOs and other specialist consultancies continues to evolve and transactions such as this are a key driver for the growth of Pharmaceutical Services companies. "We are pleased to have assisted capiton AG in the divestment...
LONDON, (informazione.news - comunicati stampa - servizi)

The pharmaceutical services sector that includes CROs, CDMOs and other specialist consultancies continues to evolve and transactions such as this are a key driver for the growth of Pharmaceutical Services companies.

" ," said . "

For further information, please contact:

Adrian Dawkes
Managing Director
adrian@pharmaventures.com


capiton is an independent, owner-managed private equity firm with a total fund volume of €1.6 billion. The current investment portfolio of capiton AG includes 18 medium-sized companies. As an equity partner, capiton supports management buy-outs and growth financing for established medium-sized businesses.

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances.

For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.

PharmaVentures' deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning.

PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures' services include:

PharmaVentures is based in London, UK , and employs over 30 professionals and has associates in Europe and Asia-Pacific .

NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

For more details, visit  https://www.pharmaventures.com

Follow us on LinkedIn:  https://www.linkedin.com/company/pharmaventures/

Photo - https://mma.prnewswire.com/media/2703311/PharmaVentures.jpg
Logo - https://mma.prnewswire.com/media/2703310/PV_Logo.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/pharmaventures-acts-as-exclusive-ma-advisor-to-the-pe-firm-capiton-ag-on-the-successful-sale-of-mip-pharmas-sterile-production-facility-to-famar-group-302473613.html

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili